Oral factor xa inhibitors for the prevention of stroke in atrial fibrillation

Current Opinion in Cardiology

Volumn 25, Issue 4, 2010, Pages 312-320

  Piccini, Jonathan P ^a   Lopes, Renato D ^a   Mahaffey, Kenneth W ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

anti factor Xa; anticoagulants; atrial fibrillation; stroke; warfarin

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; BETRIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; DIGOXIN; DU 176B; ENOXAPARIN; RANITIDINE; RIVAROXABAN; WARFARIN; XIMELAGATRAN; YM 150;

ANTICOAGULANT THERAPY; BLEEDING; DIARRHEA; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; DYSPEPSIA; EMBOLISM; HEART ATRIUM FIBRILLATION; HUMAN; LIVER TOXICITY; LOADING DRUG DOSE; NAUSEA; PRIORITY JOURNAL; REVIEW; STROKE;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZAMIDES; FACTOR XA; FIBRINOLYTIC AGENTS; HUMANS; MORPHOLINES; PYRAZOLES; PYRIDINES; PYRIDONES; STROKE; THIAZOLES; THIOPHENES; THROMBOEMBOLISM; WARFARIN;

EID: 77953809022     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32833a524f     Document Type: Review

References (59)

1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) study. JAMA 2001; 285:2370-2375.
2. Lakshminarayan K, Solid CA, Collins AJ, et al. Atrial fibrillation and stroke in the general medicare population: a 10-year perspective (1992 to 2002). Stroke 2006; 37:1969-1974.
3. Lee WC, Lamas GA, Balu S, et al. Direct treatment cost of atrial fibrillation in the elderly American population: a Medicare perspective. J Med Econ 2008; 11:281-298.
4. Thrall G, Lane D, Carroll D, Lip GYH. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med 2006; 119:448e1-448e19.
5. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002; 113:359-364.
6. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics: 2010 update. A report from the American Heart Association. Circulation 2009; 119:480-486.
7. Dulli DA, Stanko H, Levine RL. Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology 2003; 22:118-123.
8. Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham study. Stroke 1996; 27:1760-1764.
9. Paciaroni M, Agnelli G, Caso V, et al. Atrial fibrillation in patients with first-ever stroke: frequency, antithrombotic treatment before the event and effect on clinical outcome. J Thromb Haemost 2005; 3:1218-1223.
10. Caro JJ. An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation. Am J Manag Care 2004; 10:S451-S458; discussion S458-461.
11. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:160S-198S.
12. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857-867.
13. Connolly S, Pogue J, Hart R, et al.; ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367:1903-1912.
14. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165:1095-1106.
15. Estes NA 3rd, Halperin JL, Calkins H, et al. ACC/AHA/Physician consortium 2008 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation): developed in collaboration with the Heart Rhythm Society. Circulation 2008; 117:1101-1120.
16. Gage BF, Boechler M, Doggette AL, et al. Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation. Stroke 2000; 31:822-827.
17. Birman-Deych E, Radford MJ, Nilasena DS, Gage BF. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke 2006; 37:1070-1074.
18. Albers GWYJ, Belew KM, Bittar N, et al. Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals. Arch Intern Med 1996; 156:2311-2316.
19. Go AS, Hylek EM, Borowsky LH, et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Ann Intern Med 1999; 131: 927-934.
20. Lopes RD, Starr A, Pieper CF, et al. Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes. Am J Med 2009; 123:134-140.
21. Lopes RD, Elliott LE, White HD, et al. Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. Eur Heart J 2009; 30:2019-2028.
22. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:546S-592S.
23. Piccini JP, Hernandez AF, Zhao X, et al. Quality of care for atrial fibrillation among patients hospitalized for heart failure. J Am Coll Cardiol 2009; 54:1280-1289.
24. Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 2008; 1:84-91.
25. Albers GW, Diener HC, Frison L, et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005; 293:690-698.
26. van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002; 288:2441-2448.
27. Rose AJ, Ozonoff A, Grant RW, et al. Epidemiology of subtherapeutic anticoagulation in the United States. Circ Cardiovasc Qual Outcomes 2009; 2:591-597.
28. Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost 2003; 1:1504-1514.
29. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-1151.
30. Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care 2009; 15:e22-e33.
31. Gage BF. Can we rely on RE-LY? N Engl J Med 2009; 361:1200-1202.
32. Wastall P, Nepal S, Frost C. A randomized, placebo and positive controlled, crossover study to determine the effect of repeated doses of the factor Xa inhibitor apixaban on the QTc interval [abstract PII-18]. Clin Pharmacol Ther 2008; 83:S48.
33. Pinto DJ, Orwat MJ, Koch S, et al. Discovery of 1-(4-methoxyphenyl)-7- oxo-6- (4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c] pyridine- 3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 2007; 50:5339-5356.
34. Wong PC, Crain EJ, Xin B, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic, and antihemostatic studies. J Thromb Haemost 2008; 6:820-829.
35. Lassen MR, Davidson BL, Gallus A, et al. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007; 5:2368-2375.
36. Buller H, Deitchman D, Prins M, Segers A. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 2008; 6:1313-1318.
37. Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009; 361:594-604.
38. Alexander JH, Becker RC, Bhatt DL, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009; 119:2877-2885.
39. Lopes R, Alexander J, Al-Khatib S, et al. Apixaban for Stroke Prevention in Atrial Fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010; 159:331-339.
40. Abe K, Siu G, Edwards S, et al. Animal models of thrombosis help predict the human therapeutic concentration of PRT54021, a potent oral factor Xa inhibitor [abstract 901]. Blood 2006; 108.
41. Turpie AG, Bauer KA, Davidson BL, et al. A randomized Evaluation of Betrixaban, an Oral Factor Xa Inhibitor, for Prevention of Thromboembolic Events After Total Knee Replacement (EXPERT). Thromb Haemost 2009; 101:68-76.
42. Exzekowitz M, Connolly S, Diaz R, et al. A Phase 2, Randomized, Parallel Group, Dose-Finding, Multicenter, Multinational Study of the Safety, Tolerability and Pilot Efficacy of Three Blinded Doses of the Oral Factor Xa Inhibitor Betrixaban Compared with Open-Label Dose-Adjusted Warfarin in Patients with Nonvalvular Atrial Fibrillation (EXPLORE-Xa). American College of Cardiology 59th Annual Scientific Session; Atlanta, GA; 2010.
43. Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010 [Epub ahead of print].
44. Weitz J, Connolly S, Kunitada S, et al. Randomised, parallel group, multicentre, multinational study evaluating safety of DU-176b compared with warfarin in subjects with nonvalvular atrial fibrillation. ASH Annual Meeting; San Francisco; 2008.
45. Piccini JP, Patel MR, Mahaffey KW, et al. Rivaroxaban, an oral direct factor Xa inhibitor. Expert Opin Investig Drugs 2008; 17:925-937.
46. Biemond BJ, Perzborn E, Friederich PW, et al. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939): an oral, direct factor Xa inhibitor. Thromb Haemost 2007; 97:471-477.
47. Roehrig S, Straub A, Pohlmann J, et al. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]- 1,3-oxazolidin- 5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem 2005; 48:5900-5908.
48. Hader S, Graff J, Hentig N, et al. Effects of BAY 59-7939, an oral, direct factor Xa inhibitor, on thrombin generation in healthy volunteers. Pathophysiol Haemost Thromb 2004; 33 (Suppl 2):97.
49. Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939: an oral, direct factor Xa inhibitor - after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005; 61:873-880.
50. Kubitza D, Mueck W, Becka M. Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation. Drug Saf 2008; 31:67-77.
51. Agnelli G, Gallus A, Goldhaber SZ, et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with Acute Symptomatic Deep-Vein Thrombosis) study. Circulation 2007; 116:180-187.
52. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372:31-39.
53. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358:2765-2775.
54. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358:2776-2786.
55. Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373:1673-1680.
56. The Executive Steering Committee on behalf of the ROCKET AF study investigators. Rivaroxaban-Once daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010; 159:340-347.e1.
57. Iwatsuki Y, Shigenaga T, Moritani Y, et al. Biochemical and pharmacological profiles of YM150, an oral direct factor Xa inhibitor [abstract 911]. Blood 2006; 108.
58. Eriksson BI, Turpie AGG, Lassen MR, et al. A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery. J Thromb Haemost 2007; 5:1660-1665.
59. Jackson K, Gersh BJ, Stockbridge N, et al. Antithrombotic drug development for atrial fibrillation: proceedings, Washington, DC, July 25-27, 2005. Am Heart J 2008; 155:829-840.